NBI-98854-HD3005: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease

Project: Research project

Project Details

StatusActive
Effective start/end date1/13/20 → 1/31/26

Funding

  • Huntington Study Group Ltd. (NBI-98854-HD3005-Amendment-3 // NBI-98854-HD3005-Amendment-3)
  • Neurocrine Biosciences, Inc. (NBI-98854-HD3005-Amendment-3 // NBI-98854-HD3005-Amendment-3)